| Name | Title | Contact Details |
|---|
Atomic Provisions is a restaurant group that exists to nourish our staff, guests and community with simple-perfected food and service...one slice, one biscuit, one ice cream and one beer at a time. We are growing...and with us you can grow too!
We are a business and technology consulting firm that specializes in IT, Healthcare, Finance and Construction. We vet businesses, products and people to enable our clients to select the best partners for their business endeavors. Whether youre looking to augment your staff to scale new business growth, enhance your physical and cyber security, or solve complex business problems, Talent Scout is here to connect you to the best business solutions.
Our number one priority is successfully creating and providing essential services and support for limited companies in the UK. Our straightforward process can have your company set up in a matter of hours!
At the Gibraltar International Bank, we believe that empowering you to manage your money easily is key. We have invested in state-of-the-art technology and online banking so that you can conduct your banking in whatever situation you may find yourself. There really is so much that we can offer both personal and corporate clients. To discover what we can do for you, just get in touch using the details below. We would love to hear from you. Phone +350 (200) 13900 Email gibraltar@gibintbank.gi
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.